PsychonautWiki Archive

2-Aminoindane

Revision as of 14:45, 26 September 2015 by >Oskykins (Text replacement - "Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption." to "Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined...)

2-Aminoindane (2-AI) is a psychoactive drug and research chemical with stimulant properties. It is an analogue of amphetamine.[1]

2-Aminoindane
Chemical Nomenclature
Common names 2-AI
Systematic name 2,3-Dihydro-1H-inden-2-amine
Class Membership
Psychoactive class Stimulant
Chemical class Aminoindane
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 3 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 40 mg
Heavy 40 mg +
Duration
Total 1 - 2 hours
Onset 10 - 30 minutes
After effects 2 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Stimulants
MDMA
Cocaine

Very little is known about this substance, but it has recently become freely available through online research chemical vendors where it is being sold as a designer drug.

Chemistry

2-AI, or 2-Aminoindane, is a structural analogue of amphetamine. It features the R3 terminal carbon of the propane chain of amphetamine bound to the benzene ring. This creates an indane group, a bicyclic moeity containing a benzene ring fused to a pentane ring. 2-AI contains an amino group NH2 bound to R2 of the indane ring thus giving it the name 2-aminoindane. 2-AI is structurally analogous to NM2AI, lacking the N-substituted methyl group.

Pharmacology

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based upon its structure and subjective effect similarities to other stimulants such as amphetamine, methamphetamine and 2-FMA. 2-AI most likely acts as both a dopamine and norepinephrine reuptake inhibitor. This means it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

The physical effects of 2-AI can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:

  • Stimulation - In terms of its effects on the physical energy levels of the user, 2-AI is usually considered to be energetic and stimulating in a fashion that is similar to that of amphetamine but stronger than that of modafinil or caffeine. It is similar yet distinct from the stimulation experienced on MDMA, encouraging physical activities such as dancing, socializing, running, or cleaning. The particular style of stimulation which 2-AI presents can be described as forced. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily bodily shakes and vibrations become present, resulting in extreme shaking of the entire body, unsteadiness of the hands, and a general lack of motor control.
  • Pain relief - Many anecdotal reports suggest that this compound may suppress pain in a fashion somewhat similar to opioids without the distinct physical euphoria.
  • Increased heart rate
  • Dehydration
  • Appetite suppression
  • Nausea
  • Temporary erectile dysfunction
  • Increased perspiration

Cognitive effects

The cognitive effects of 2-AI can be broken down into several components which progressively intensify proportional to dosage. The general head space of 2-AI is described by many as one of mental stimulation, increased focus, and euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.

The most prominent of these cognitive effects generally include:

Visual effects

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2-AI use have not been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-AI is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 2-AI suggests that there are no negative health effects attributed to simply trying this drug at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed).

Tolerance and addiction potential

Tolerance develops rapidly with repeated usage, so periods of extended use require increasing doses of the drug in order to achieve the same effect. Addiction is a serious risk with heavy recreational use of any substituted amphetamine and compulsive redosing is extremely common.

Psychosis

Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[2] A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[3][4] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[5] Psychosis very rarely arises from therapeutic use.[6][7]

Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

General risk

2-AI is currently a grey area compound within all parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.

See also

References

  1. ↑ Structural variation and (+)-amphetamine-like discriminative stimulus properties | https://www.ncbi.nlm.nih.gov/pubmed/2068194
  2. ↑ Treatment for amphetamine psychosis | [1]
  3. ↑ Treatment for amphetamine psychosis | [2]
  4. ↑ Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  5. ↑ Treatment for amphetamine psychosis | [3]
  6. ↑ Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
  7. ↑ http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf
  8. ↑ Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
Retrieved from "http://psy.st/w/index.php?title=2-Aminoindane&oldid=46025"